OpenAI acquires startup Orchestra Bio to beef up its biotech business
OpenAI says it's adding Orchestra's team and technology to work on Rosalind, its AI model for life sciences research, and to its related Rosalind Workbench tool, a harness that aims to help researchers plan experiments and analyze results.
AI Summary
OpenAI has acquired biotech startup Orchestra Bio to enhance its AI model for life sciences research, Rosalind, and its associated tool, Rosalind Workbench. Orchestra develops AI agents to assist biotech companies with drug discovery tasks such as financial tracking and clinical trial scheduling. This acquisition reflects a trend where major AI labs are increasingly creating software for large industries like pharmaceuticals.